Aldeyra Therapeutics, Inc. (ALDX) Stock Price & Analysis
Aldeyra Therapeutics, Inc. (ALDX) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $0.7217 (+7.54%), as of the Nov 19, 2026 trading session; market cap $43.6M.
Educational signal · not a buy or sell recommendation · How to read this
Aldeyra Therapeutics, Inc. · ALDX · NASDAQ
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated ocular and systemic diseases. Their lead product, reproxalap, targets dry eye disease and allergic conjunctivitis and is currently in Phase III clinical trials.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Aldeyra Therapeutics (ALDX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite growth, but a fragile balance sheet and a full valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Fragile; Valuation: Full; Growth Durability: Compounding; Momentum: Slipping.
- EPS beat 6 of the last 8 reports
- Altman Z -15.06 · Piotroski F 2
- ROE -0.0% · ROA -0.0% · current ratio 5.45 · earnings yield -49.2% · free-cash-flow yield -49.3%
Holding back: balance-sheet strain, weak price trend
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 32 | Weak | |
| 32 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.7217 | |
| Change on the day | +7.54% | |
| Market capitalisation | $43.6M | — |
| Shares traded on the day | 847.0K |
Price & events
Other perspectives
Council score for Aldeyra Therapeutics (ALDX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Aldeyra Therapeutics (ALDX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aldeyra Therapeutics, Inc. (ALDX) is listed on NASDAQ. It employs 6 people. The market values it at $43.6M.
What do the latest results show for Aldeyra Therapeutics (ALDX)?
Short answer · as of
Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $0 | -$4M | -$0.06 (diluted) |
| Q2 FY2026 | $0 | -$5M | -$0.09 (diluted) |
| Q1 FY2026 | $0 | -$3M | -$0.06 (diluted) |
| Q4 FY2025 | $0 | -$6M | -$0.11 (diluted) |
What are the financial strengths and risks for Aldeyra Therapeutics (ALDX)?
Short answer · as of
The MoonshotScore pillars rate durable growth as strengths. What is holding it back is balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -15.06 · Piotroski F 2. Trailing ratios: ROE -0.0% · ROA -0.0% · current ratio 5.45 · earnings yield -49.2% · free-cash-flow yield -49.3%.
Data-derived red flags
- Listing risk — at $0.7217 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -15.06 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-0.0%) — the business is not currently generating profit on shareholder capital.
How does Aldeyra Therapeutics compare with its peers?
Short answer
Aldeyra Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1382.75 Nov 18, 2026 | $1.23T | 98 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $536.45 Nov 18, 2026 | $136B | 90 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| Aldeyra Therapeutics (ALDX) — this page | $0.7217 | $43.6M | 32 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 11, 2026
- Transactions
- 20
- Identified insiders
- 9
- Purchases
- 3
- Sales
- 0
- Other transactions
- 17
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ALDX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ALDX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Aldeyra Therapeutics (ALDX)?
- Aldeyra Therapeutics Independent Board Chair Purchases Shares
- Aldeyra Therapeutics Requests FDA Transfer Of ADX-2191 Ind Review For PVRL To Division Of Hematologic Malignancies 2; Withdraws Special Protocol Assessment For ADX-2191 In PVRL; While Jurisdictional Request Is Pending, Does Not Expect To Initiate SPA Clinical Trial For ADX-2191 In PVRL; Regulatory Path For ADX-2191 In PVRL Is Uncertain And May Be Delayed
- Barclays PLC Files Schedule 13G for Aldeyra Therapeutics
Aldeyra Therapeutics Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ALDX research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ALDX?
ALDX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated ocular and systemic diseases.
Is ALDX a good stock to buy?
Stock Expert AI does not rate ALDX buy, sell or hold. Aldeyra Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ALDX stock price today?
The last price recorded for Aldeyra Therapeutics, Inc. (ALDX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about ALDX stock?
Analyst coverage of Aldeyra Therapeutics, Inc. (ALDX) typically focuses on the potential of its lead product candidate, reproxalap, and its broader clinical pipeline.
What are the key factors to evaluate for ALDX?
Aldeyra Therapeutics, Inc. (ALDX) holds a MoonshotScore in the low range. Analysts target $9.67 (+1240%). Reproxalap, Aldeyra's lead product candidate, is in Phase III clinical trials for dry eye disease and allergic conjunctivitis, targeting a large patient population. Not financial advice.
How frequently does ALDX data refresh on this page?
ALDX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ALDX's recent stock price performance?
Aldeyra Therapeutics, Inc. (ALDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel RASP modulation technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALDX overvalued or undervalued right now?
Aldeyra Therapeutics, Inc. (ALDX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ALDX?
Fractional-share availability for Aldeyra Therapeutics, Inc. (ALDX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 11 figures on this page — 6 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com